p38 Mitogen Activated Kinases (p38MAPK) Activation & Skeletal Muscle Function

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

Megan Ye Li Yuen*, Dr. Audrey Brown, Prof. Mark Walker

Email: l.y.megan-yeoh2@newcastle.edu.my Student ID: 160003507 Programme of Study: MBBS (NUMed)

Introduction
Type 2 diabetes (T2D) patients have decreased skeletal muscle function when compared with age-matched non-diabetics. p38MAPK is a protein involved in cell differentiation. Interestingly, a previous study found increased p38MAPK activation in cultured skeletal muscle cells from insulin resistant T2D patients with a strong diabetes family history. When p38MAPK is deactivated in aged mice, it was found that their skeletal muscle functions could be improved.

Aim
To answer the question “Is p38MAPK activation increased in myoblasts (undifferentiated muscle cells) and myotubes (differentiated muscle cells) from an unselected group of T2D patients?”

Methods
Muscle cultures were established from 11 T2D patients and 12 age-matched controls. Protein was then extracted from myoblasts and day 7 differentiated myotubes for each culture.

Results

Graph 1: Densitometry presented as the mean ± standard error from 6 diabetic and 10 control samples for myoblasts; 10 diabetic and 9 control samples for myotubes.

Graph 2: Cell number against days of cell proliferation for control and diabetic myoblasts. This data was obtained from Dr. Brown’s experiment which used the same muscle cultures as this study.

Discussion
As this study showed that there was no significant difference in the degree of p38MAPK activation between diabetic and non-diabetic myoblasts and myotubes, the results from this study differed from those obtained from the previous study. This might be because the T2D cohort in this study consisted of subjects with different family history, diabetes durations, treatment periods, as well as treatment types. These factors might affect p38MAPK activation, suggesting that increased p38MAPK activation is restricted to a subgroup of T2D patients.

However, taking the results from Brown’s experiment as shown in Graph 2 into consideration, it is worth noting that despite having a difference in the rate of proliferation of myoblasts in the late stages between control and diabetic samples, the degree of p38MAPK activation is still similar. Therefore, the late decreased proliferation in the diabetic myoblasts does not appear to be related to altered p38MAPK activation.

Conclusion
p38MAPK activation is not increased in myoblasts and myotubes from an unselected group of T2D patients when compared with age-matched non-diabetics.

Future Work
Since there is a possibility that various factors such as family history, diabetes durations, treatment periods and treatment types, affect p38MAPK activation, it is crucial to determine which factors are directly associated with it.

Acknowledgements
Sincere thanks to Dr. Audrey Brown & Prof. Mark Walker for their guidance and support; the Institute of Cellular Medicine, Newcastle University for providing all facilities and equipment required; George Henderson and George Brown endowment funds, and Newcastle University for funding my research scholarship.

References

Figure 1: Myoblasts

Figure 2: Myotubes

Figure 3: SDS-PAGE for western blots

Figure 4: Western blots detecting phosphorylated p38MAPK (activated p38MAPK), total p38MAPK and β-actin.

Graph 1: Western blots detecting phosphorylated p38MAPK (activated p38MAPK), total p38MAPK and β-actin.